U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H25FN4O2
Molecular Weight 324.3937
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRUSOGLIPTIN

SMILES

CC(C)(CC(=O)N1CCCC1)NCC(=O)N2C[C@@H](F)C[C@H]2C#N

InChI

InChIKey=VQKSCYBKUIDZEI-STQMWFEESA-N
InChI=1S/C16H25FN4O2/c1-16(2,8-14(22)20-5-3-4-6-20)19-10-15(23)21-11-12(17)7-13(21)9-18/h12-13,19H,3-8,10-11H2,1-2H3/t12-,13-/m0/s1

HIDE SMILES / InChI

Molecular Formula C16H25FN4O2
Molecular Weight 324.3937
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.clinicalleader.com/doc/scinopharm-and-national-health-research-0001

DBPR-108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9, which is in phase I clinical trial as a potential treatment of type 2 diabetes.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
15.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.8
unhealthy, 52.59
n = 69
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: 52.59
Sex: M+F
Population Size: 69
Sources: Page: p.8
PubMed

PubMed

TitleDatePubMed
(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
2010 Jun 15
Patents

Sample Use Guides

DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:26:53 GMT 2023
Edited
by admin
on Sat Dec 16 01:26:53 GMT 2023
Record UNII
E329HG23ZT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRUSOGLIPTIN
INN  
Official Name English
prusogliptin [INN]
Common Name English
DBPR-108
Code English
(2S,4S)-4-FLUORO-1-(((2-METHYL-4-OXO-4-(PYRROLIDIN-1- YL)BUTAN-2-YL)AMINO)ACETYL)PYRROLIDINE-2-CARBONITRILE
Systematic Name English
2-PYRROLIDINECARBONITRILE, 1-(2-((1,1-DIMETHYL-3-OXO-3-(1-PYRROLIDINYL)PROPYL)AMINO)ACETYL)-4-FLUORO-, (2S,4S)-
Systematic Name English
(2S,4S)-1-(2-((1,1-DIMETHYL-3-OXO-3-(1-PYRROLIDINYL)PROPYL)AMINO)ACETYL)-4-FLUORO-2-PYRROLIDINECARBONITRILE
Systematic Name English
Code System Code Type Description
INN
11627
Created by admin on Sat Dec 16 01:26:53 GMT 2023 , Edited by admin on Sat Dec 16 01:26:53 GMT 2023
PRIMARY INN
FDA UNII
E329HG23ZT
Created by admin on Sat Dec 16 01:26:53 GMT 2023 , Edited by admin on Sat Dec 16 01:26:53 GMT 2023
PRIMARY
SMS_ID
300000032236
Created by admin on Sat Dec 16 01:26:53 GMT 2023 , Edited by admin on Sat Dec 16 01:26:53 GMT 2023
PRIMARY
NCI_THESAURUS
C179116
Created by admin on Sat Dec 16 01:26:53 GMT 2023 , Edited by admin on Sat Dec 16 01:26:53 GMT 2023
PRIMARY
CAS
1186426-66-3
Created by admin on Sat Dec 16 01:26:53 GMT 2023 , Edited by admin on Sat Dec 16 01:26:53 GMT 2023
PRIMARY
PUBCHEM
44201003
Created by admin on Sat Dec 16 01:26:53 GMT 2023 , Edited by admin on Sat Dec 16 01:26:53 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY